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1. Introduction
Phenytoin is one of the most widely-prescribed drugs for 
the treatment of epilepsy [1, 2]. It has non-linear dose-depen-
dent pharmacokinetics and is mostly excreted in bile as inac-
tive metabolites, which are then reabsorbed from the intes-
tinal tract and excreted in urine [3, 4]. The primary metabo-
lites of phenytoin are 5-(3-hydroxyphenyl)-5-phenylhydanto-
in (m-HPPH) and 5-(4-hydroxyphenyl)-5-phenylhydantoin (p-
HPPH) (see Figure 1) [4]. 
Like other drug metabolites, m-HPPH and p-HPPH have 
similar structures to their parent drug, which can cause these 
to affect the distribution, action, and protein binding by phe-
nytoin [4, 5]. Because phenytoin exhibits dose-dependent 
pharmacokinetics, the apparent half-life of phenytoin chang-
es with its dose and serum concentration. This occurs because 
phenytoin is hydroxylated in the liver by an enzymatic system 
that is saturable at high plasma levels of this drug, as occurs at 
therapeutic concentrations [6]. As a result, small increases in 
this drug’s dose may cause larger-than-expected increases in 
phenytoin’s serum concentration and apparent half-life, along 
with lower levels for its metabolites [6].
When phenytoin is present in blood, it is highly bound to 
the carrier protein human serum albumin (HSA) [3, 7]. A few 
reports have indicated that phenytoin interacts at the warfarin-
azapropazone site of HSA [8, 9], while others have noted com-
petition between phenytoin and digitoxin through the digitox-
in site on HSA [10]. Recently Chen et al. have reported that 
phenytoin interacts at several sites on this protein [7], with as-
sociation equilibrium constants at the indole-benzodiazepine 
and digitoxin sites of 1.04 (±0.05) × 104 and 6.5 (±0.6) × 103 
M−1 at pH 7.4 and 37 °C; interactions involving allosteric ef-
fects and/or direct binding by phenytoin at the warfarin-aza-
propazone and tamoxifen sites of HSA were also noted.
Besides phenytoin, HSA is known to bind to a wide range 
of other drugs and endogenous agents [9, 11, 12]. Although 
several studies have examined the binding of phenytoin to 
HSA, there is no known work that has examined the binding of 
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HSA to the phenytoin metabolites m-HPPH and p-HPPH. This 
is of interest because 60–80% of phenytoin is metabolized into 
these forms [13]. The goal of this work is to study the binding 
of these metabolites to HSA by using high performance affi ni-
ty chromatography and columns containing immobilized HSA. 
Numerous reports using HPLC-based HSA columns have re-
ported drug-binding properties that show good agreement with 
those seen for soluble HSA [7, 14, 15]; this includes the recent 
work performed with phenytoin in Reference [7].
In this current study, self-competition studies with m-
HPPH and p-HPPH will fi rst be used to determine the num-
ber of binding regions and association equilibrium constants 
for these metabolites with HSA. The location of these bind-
ing regions will be identifi ed through studies using warfarin, 
l-tryptophan, digitoxin, and cis-clomiphene as site-selective 
probes [11, 16–19]. The competition of these phenytoin me-
tabolites with phenytoin will also be considered. This should 
result in a more complete picture of the binding of m-HPPH 
and p-HPPH to HSA and of the relationship of this binding to 
that of phenytoin and HSA.
2. Theory
2.1. General model and expressions
The binding of m-HPPH and p-HPPH to HSA was studied by 
using the chromatographic method of zonal elution [16], [18], 
[19], [20], [21] and [22]. In this technique, a competing agent 
(I) is placed in the mobile phase at a known concentration and 
continuously applied to an affi nity column containing an im-
mobilized ligand (L), such as HSA. Small amounts of an an-
alyte (A) are then injected onto this system and the retention 
time of the analyte is determined. If I and A compete for a sin-
gle binding site on L, the following reactions and equilibrium 
expressions can be used to describe the competition that takes 
place between these agents in the column.
  (1)
  (2)
  (3)
   (4)
In these equations, KAL is the association equilibrium constant 
for the binding of A to L, and KIL the association equilibrium 
constant for the binding of I to L at the site of competition be-
tween A and I [16]. The symbol [ ] represents the molar con-
centration of a solute in the mobile phase, while { } represents 
a surface concentration.
Equation (5) has been previously derived for the above 
system to describe the retention of A as the value of [I] is var-
ied [16].
    (5)
In this equation, k is the retention factor for the injected solute 
A, VM the column void volume, and mL the moles of binding 
sites involved in the competition of A with L. If linear elution 
conditions are present (i.e., the retention factor for A is inde-
pendent of the amount of injected A), Equation (5) predicts 
that a system with direct competition at a single site will give 
a plot for 1/k versus [I] that is linear. From the ratio of the 
slope to the intercept of this plot it is possible to obtain KIL, 
the association equilibrium constant for I at its site of compe-
tition with A. It is also possible to obtain KAL from the inter-
cept if independent values are available for mL and VM [16].
Figure 1. Structures of phenytoin and its metabolites, m-HPPH and p-HPPH. 
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2.2. Self-competition studies
A special case arises for the system in Eqs. (1), (2), (3) 
and (4) when A and I are the same compound. An example of 
such an experiment is shown in Figure 2(a). In this situation 
Equation (5) converts to the following form for a system with 
single site binding, where [A] is the concentration of analyte 
placed into the mobile phase [16].
    (6)
This expression again results in a linear relationship for a plot 
of 1/k versus [A]. However, the reciprocal of the slope now 
gives the effective concentration of binding sites in the col-
umn (mL/VM), and the ratio of the slope to the intercept pro-
vides KAL. This makes such an experiment valuable in deter-
mining both the association equilibrium constant for an ana-
lyte with L and the amount of ligand sites present for this ana-
lyte in an affi nity column [7, 11, 12, 16]. 
2.3. Direct competition with site-selective probes
Another advantage of zonal elution is it can be used to char-
acterize site-specifi c equilibrium constants for an analyte that 
has multiple binding sites on a ligand. For instance, this has been 
used in recent work with phenytoin to show that this drug has at 
least two binding sites on HSA, as demonstrated by its competi-
tion with the site-selective probes l-tryptophan and digitoxin [11, 
15]. This type of experiment is illustrated in Figure 2(b).
The simplest case for this type of experiment is one in 
which a 1:1 interaction occurs between the injected analyte 
(A) and competing agent (I) on the immobilized ligand. As 
demonstrated previously [7, 19], this situation is described by 
Equation (5) even if I (but not A) has multiple binding regions 
on the ligand. In this case, the value of KIL that is obtained 
from a plot of 1/k versus [I] gives the association equilibri-
um constant for I at its site of competition of A. If A is known 
to bind to a given region on the ligand, this allows the compe-
tition of I at that site to also be examined and quantitated. By 
using different probe compounds as the injected analyte, each 
with a different binding region on the ligand, the interactions 
of I at other sites on the same ligand can be examined in the 
same manner [4, 11, 12, 16, 18, 19].
2.4. Detection of allosteric interactions
It is important to note that a linear response to Equation 
(5) will be obtained only if there is direct competition between 
A and I at a single type of binding site on L. If this is not the 
case, then deviations from this linear response will be ob-
served. One situation in which deviations can occur is if neg-
ative or positive allosteric effects are present. For instance, an 
allosteric effect can occur if the ligand has two distinct sites 
for A and I that affect one another.
If A or I is in the presence of L alone, then the association 
equilibrium constants that will be observed for these solutes 
will be KAL and KIL, respectively, as represented by the reac-
tions in Equations (1) and (2). However, if both A and I are 
present and their sites are allosterically linked, then the bind-
ing of A or I to L may cause a change in binding of the oth-
er agent at its respective site on the same ligand and result in a 
change in their association equilibrium constants [16, 20]. For 
a positive allosteric effect, this gives a non-linear response for 
a plot of 1/k versus [I ], where k increases with [I ]. For a neg-
ative allosteric effect, the result is also a non-linear plot for 1/
k versus [I ], but with k now decreasing as [I ] increases. These 
trends make it relatively easy to use affi nity columns to quali-
tatively detect the presence of allosteric effects during solute-
ligand binding [7, 16]. In some situations, quantitative infor-
mation on such effects can also be obtained [23].
3. Experimental
3.1. Reagents
The phenytoin (99% pure), m-HPPH (>98% pure), p-
HPPH (>98% pure), l-tryptophan (>98% pure), β-cyclodex-
trin (β-CD, >98% pure), digitoxin (97% pure) and HSA (99% 
pure, essentially fatty acid free) were from Sigma (St. Louis, 
MO, USA). HPLC-grade dimethylsulfoxide (>99% pure) was 
from Alfa Aesar (Ward Hill, MA, USA). The cis-clomiphene 
was supplied by the Marion Merrell Dow Research Institute 
(Cincinnati, OH). The R-warfarin (>99% pure) was from Ul-
trafi ne (Manchester, England). Nucleosil Si-300 (7 μm parti-
Figure 2. Typical chromatograms obtained in: (a) self-competition studies, as 
illustrated with data for m-HPPH; and (b) competition studies with a site-se-
lective probe, as represented by injections of l-tryptophan in the presence of 
mobile phases containing various concentrations of p-HPPH. The experimen-
tal conditions are given in Section 3. 
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cle size, 300 Å pore size) was obtained from Macherey-Na-
gel (Duren, Germany). Reagents for the bicinchoninic acid 
(BCA) protein assay were from Pierce (Rockford, IL, USA). 
Other chemicals were reagent-grade or better. All aqueous so-
lutions were prepared using water purifi ed by a Nanopure sys-
tem (Barnstead, Dubuque, IA, USA).
3.2. Apparatus
The chromatographic system consisted of a Jasco PU-
980 pump (Easton, MD, USA), a ThermoSeparations AS3000 
autosampler (Riviera Beach, FL, USA), and a Milton Roy 
SM3100 UV–vis absorbance detector (Riviera Beach, FL, 
USA). The columns were maintained at 37 °C with a water 
jacket from Alltech (Deerfi eld, IL, USA) and water circulator 
from Brinkmann (Westbury, NY, USA). Chromatographic data 
were collected using an in-house program written in Labview 
5.1 (National Instruments, Austin, TX, USA). Retention times 
were measured using PeakFit 4.12 (Jandel Scientifi c Software, 
San Rafael, CA, USA). All columns were downward slurry-
packed with an HPLC column slurry packer from Alltech.
3.3. Methods
3.3.1. Column preparation
The immobilized HSA support was prepared as described 
previously [24]. In this technique, Nucleosil Si-300 was fi rst 
converted to diol-bonded silica [25]. This gave 306 (±3) μmol 
diol groups (±1 S.D.) per gram of silica, as determined in trip-
licate by an iodometric capillary electrophoresis assay [26]. 
HSA was immobilized onto a portion of this support by the 
Schiff base method in the following manner. The diol-bond-
ed silica (about 1 g being required per column) was placed 
in 10 mL of a 90:10 mixture of acetic acid and water along 
with a mass of sodium periodate equal to the mass of diol sili-
ca (i.e., 1 g sodium periodate per 1 g diol-bonded silica). This 
mixture was shaken for 2 h at room temperature using a wrist 
action shaker, followed by centrifugation and washing of the 
resulting aldehyde-activated support several times with de-
ionized water. Next, 10 mL of pH 6.0, 0.1 M phosphate buf-
fer was used to resuspend this support. This mixture was de-
gassed under vacuum for 15 min and combined with 50 mg 
HSA and 25 mg sodium cyanoborohydride per gram of silica. 
The resulting mixture was kept in suspension by using a rota-
ry stirrer and allowed to react at 4 °C for fi ve days.
After immobilization, the resulting HSA support was 
washed three times with pH 8.0, 0.1 M phosphate buffer. Any 
remaining aldehyde groups on the support were reduced by 
adding 17 mg sodium borohydride per gram of silica, which 
was added slowly in three portions. This new mixture was 
placed on a wrist action shaker for 2 h at room temperature. 
The silica was then washed three times with pH 8.0, 0.1 M 
phosphate buffer containing 0.5 M sodium chloride, followed 
by several washes with pH 7.4, 0.067 M phosphate buffer. The 
fi nal support was stored in pH 7.4, 0.067 M phosphate buffer 
at 4 °C until use. A control support was prepared in a similar 
manner by taking diol-bonded silica through the entire immo-
bilization procedure but with no HSA being added.
The HSA and control supports were downward slurry-
packed at 4000 psi (28 MPa) into separate 4.5 cm × 4.6 mm 
i.d. stainless steel columns using pH 7.4, 0.067 M potassium 
phosphate buffer as the packing solution. A portion of each re-
maining support was washed three times with deionized wa-
ter, dried in a vacuum oven, and assayed in triplicate by the 
BCA method for its protein content, using HSA as the stan-
dard and the control support as the blank [27]. This measure-
ment gave an estimated protein content for the HSA support 
of 28 (±2) mg HSA per gram of silica.
Both the HSA and control columns were used within four 
months of preparation and over approximately 270 chromato-
graphic runs. The stability of the HSA column was checked 
periodically by monitoring the retention factors for m-HPPH 
and p-HPPH in pH 7.4, 0.067 M phosphate buffer at 37 °C. 
Only a 13–38% decrease in these retention factors was not-
ed during the entire course of this study. Similar experiments 
demonstrated that there was no signifi cant change in the col-
umn void time (i.e., <2%) during these studies.
3.3.2. Chromatographic studies
All chromatographic experiments in this report were per-
formed at 37 °C and 1 mL/min, unless otherwise noted. No 
measurable changes in retention factors were seen when using 
lower fl ow rates (i.e., down to 0.3 mL/min), indicating that the 
given fl ow rate conditions were suitable for equilibrium con-
stant measurements [7]. The typical backpressures for the HSA 
and control column under these conditions were 520–670 psi 
(4–5 MPa). All sample injections were made with a 5 μL sam-
ple loop unless otherwise indicated. The detection wavelengths 
were as follows: p-HPPH and m-HPPH, 203 nm; phenytoin, 
205 nm; l-tryptophan, 213 nm; R-warfarin, 308 nm, digitox-
in, 205 nm; dimethylsulfoxide, 210 nm; and cis-clomiphene, 
204 nm. Retention times were determined by using the fi rst 
statistical moment of each chromatographic peak.
The column void time was determined by injecting di-
methylsulfoxide as a non-retained solute. Similar experiments 
were used to correct for any non-specifi c binding by inject-
ing the analytes on the control column. The retention factors 
measured for each analyte on the control column were then 
subtracted from those measured on the HSA column under 
the same set of experimental conditions. This correction for 
non-specifi c binding was 3–28% of the total retention mea-
sured on the HSA column for a given analyte. All retention 
times were also corrected for the time required for solutes to 
pass through the extra-column volume of the system, as de-
termined by making injections of dimethylsulfoxide when no 
column was present.
All samples and mobile phases were prepared using pH 
7.4, 0.067 M phosphate buffer, with 2–4 replicates of all sam-
ples being injected under each set of conditions. The self-
competition zonal elution studies with m-HPPH and p-HPPH 
were performed by applying solutions containing 0 to 40 μM 
m-HPPH or p-HPPH to the HSA and control columns while 
injecting 50 μM solutions of these same analytes. Zonal elu-
tion studies investigating the competition of phenytoin with 
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its metabolites were fi rst performed by making injections of 
50 μM phenytoin in the presence of 0–40 μM m-HPPH or p-
HPPH in the mobile phase. The roles of these analytes were 
then reversed by placing 0–35 μM phenytoin in the mobile 
phase while injecting 30–35 μM m-HPPH or p-HPPH. Zon-
al elution studies examining the competition between l-tryp-
tophan or R-warfarin with m-HPPH and p-HPPH were per-
formed in a similar manner, using injections of 10–100 μM l-
tryptophan or 20 μM R-warfarin as the sample.
The next set of experiments examined the use of digitox-
in and cis-clomiphene as injected probes in the presence of m-
HPPH or p-HPPH in the mobile phase. This was accomplished 
by using β-CD in the mobile phase to aid in the solubility of 
digitoxin and cis-clomiphene [7, 11], as used in previous work 
with these probes on other HSA columns [11, 18]. For these ex-
periments, mobile phases containing 0–30 μM m-HPPH or p-
HPPH were prepared in solutions of 2 mM or 0.88 mM β-CD, 
respectively; pH 7.4, 0.067 M phosphate buffer samples contain-
ing 5 μM digitoxin or cis-clomiphene in each of these respective 
mobile phases were also prepared. These samples were applied 
using an injection volume of 20 μL and a fl ow rate of 0.5 mL/
min or 2 mL/min for digitoxin and cis-clomiphene, respectively.
To ensure that linear elution conditions were present dur-
ing this work, various concentrations (range, 5–100 μM) for 
each analyte were injected onto both the HSA and control col-
umn in pH 7.4, 0.067 M phosphate buffer while their resulting 
retention times were measured. No signifi cant shifts in these 
retention factors (i.e., random variations of less than 3%) were 
noted over this range of concentrations. Solutions containing 
l-tryptophan were used on the same day as their preparation. 
All other samples were used within two months of preparation 
and stored at 4 °C in pH 7.4, 0.067 M phosphate buffer. Each 
solution was sonicated and degassed under vacuum for at least 
15 min prior to use in chromatographic experiments.
4. Results and discussion
4.1. Self-competition studies for m-HPPH and p-HPPH
The fi rst set of experiments in this study used zonal elution 
to examine the self-competition of m-HPPH and p-HPPH on 
HSA. This was performed by injecting each of these phenyt-
oin metabolites into the presence of a known concentration of 
the same metabolite in the mobile phase. An example of such a 
study is given in Figure 2(a), and the results are summarized in 
Table 1. Although the retention factors measured in these stud-
ies were relatively low (range, 1.22–2.17), the precision of these 
retention factors (±0.5–1.4%, one relative standard deviation) 
was more than suffi cient to allow the shifts in the m-HPPH and 
p-HPPH peaks to be observed and determined in a reproduc-
ible fashion. The retention data obtained in these experiments 
were analyzed according to a 1:1 direct competition model by 
using Equation (6). The graphs this produced are given in Fig-
ure 3. It was found that plots of 1/k versus [A] were linear for 
both metabolites, with correlation coeffi cients for m-HPPH and 
p-HPPH of 0.9971 (n = 7) and 0.9942 (n = 7), respectively. The 
best-fi t intercepts for both metabolites were within one standard 
deviation of the true intercepts, giving differences of only 0.2 
and 1.1% in these values for m-HPPH and p-HPPH. 
The linearity of the plots in Figure 3 and the agreement 
between the actual and best-fi t intercepts of these plots sup-
ports a model in which both phenytoin metabolites are inter-
acting at only one major site on HSA. From the slope/inter-
cept ratios of these plots, it was possible to obtain the asso-
ciation equilibrium constants for m-HPPH and p-HPPH with 
HSA. This gave estimated values of 4.0 (±0.1) × 103 M−1 and 
5.2 (±0.3) × 103 M−1, respectively, at pH 7.4 and 37 °C. The 
23% difference in these constants was statistically signifi -
cant and indicated that the different positions of the hydroxyl 
groups on m-HPPH and p-HPPH had a measurable effect on 
the binding of these metabolites to HSA. It is also important 
Figure 3. Results of self-competition zonal elution studies for: (a) m-HPPH; 
and (b) p-HPPH, as plotted according to Equation (6). The experimental con-
ditions are given in the text. The best-fi t lines were: (a) y = 0.00256 (±0.000
10) x + 0.7188 (±0.0019); and (b) y = 0.0033 (±0.0002) x + 0.6285 (±0.0029),
 with correlation coeffi cients of 0.9971 (n = 7) and 0.9942 (n = 7), respective-
ly. The error bars represent a range of ±1 S.D. 
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to note that these values are signifi cantly less (i.e., 20–68% 
lower) than the association equilibrium constants that have 
been measured on similar columns for phenytoin [7].
As noted in recent theoretical studies [28, 29], the observed 
peaks in self-competition studies are actually due to analyte in 
the mobile phase that has been displaced by the sample rath-
er than due to the injected analyte, which elutes slightly later 
as a normally unobservable mass peak. This means the reten-
tion factors in Table 1 are lower than those for the true peak of 
interest (i.e., the mass peak), which would give high estimates 
for association equilibrium constants determined according to 
Equation (6). However, it is possible to determine the maxi-
mum size of this error based on the estimated separation factor 
(α) between the mass peak and displacement peak, as described 
in Reference [28]. Under the conditions used in this study this 
gave a maximum difference of only 7–12% in the desired and 
observed retention factors. This same issue was not a problem 
in later studies using site-selective probes or phenytoin as com-
peting agents (see Sections 4.2 and 4.3) since in these experi-
ments the injected analyte was different from the competing 
agent and had a mass peak that could be observed directly.
4.2. Competition of phenytoin metabolites with 
site-selective probes for HSA
The next group of studies sought to determine the loca-
tion of the major binding regions for m-HPPH and p-HPPH 
on HSA. This was accomplished by examining the competi-
tion of these phenytoin metabolites with l-tryptophan and R-
warfarin, which are often used as probes for the indole-benzo-
diazepine and warfarin-azapropazone sites of HSA (i.e., Sud-
low sites I and II) [15, 17, 18]. The data obtained in these ex-
periments are summarized in Table 2. The fi rst series of ex-
periments used injections of l-tryptophan in the presence of 
m-HPPH or p-HPPH as a mobile phase additive, as illustrated 
earlier in Figure 2(b). A plot of 1/k versus [I] was then made 
for each phenytoin metabolite. According to Equation (5), this 
type of plot should yield a straight line if the probe and mo-
bile phase additive are competing at a single type of site on 
the immobilized ligand. 
The plots obtained when using l-tryptophan as a site-selec-
tive probe are shown in Figure 4, where both phenytoin me-
tabolites gave linear relationships when their data were ana-
lyzed according to Equation (5). The correlation coeffi cients of 
the graphs for m-HPPH and p-HPPH were 0.9956 (n = 6) and 
0.9986 (n = 7), respectively. In addition, both plots gave best-fi t 
intercepts that agreed within one standard deviation with the ac-
tual intercepts, with values that differed by only 0.3 and 0.4%. 
This type of fi t indicated that both metabolites had direct 1:1 
competition with l-tryptophan. This led to the conclusion that 
the indole-benzodiazepine site (i.e., Sudlow site II) was the ma-
jor binding region on HSA for both m-HPPH and p-HPPH. 
From the intercept and slope of the plots in Figure 4, it was 
possible to obtain additional estimates of the association equi-
librium constants for m-HPPH and p-HPPH with HSA. This 
gave association equilibrium constants of 2.3 (±0.1) × 103 M−1 
and 6.2 (±0.1) × 103 M−1, respectively, for these metabolites at 
pH 7.4 and 37 °C. These values, which were now measured for 
these metabolites specifi cally at the indole-benzodiazepine site, 
are in reasonable agreement with those determined earlier from 
the self-competition studies. These results again indicate that p-
HPPH has stronger binding to HSA than m-HPPH and that both 
metabolites had weaker binding to HSA than phenytoin [7].
Similar studies were conducted using R-warfarin as a site-
selective probe for the warfarin-azapropazone site of HSA 
(i.e., Sudlow site I). However, in this case only small random 
variations (±2%) in the retention factor of the injected probe 
were noted as the mobile phase concentration of m-HPPH or 
p-HPPH was varied. This indicated that these phenytoin me-
tabolites were not binding at the warfarin-azapropazone site. 
These results also indicated that these metabolites did not have 
any appreciable allosteric effects on the binding of R-warfa-
rin to HSA. This result differs from previous studies with R-
warfarin and phenytoin, where allosteric effects plus possible 
direct competition were shown to exist between these agents 
during their interactions with HSA [7].
Additional studies were conducted to investigate any in-
teractions of the phenytoin metabolites at the digitoxin and 
tamoxifen sites of HSA. This was accomplished by making 
injections of digitoxin (a digitoxin site probe) or cis-clomi-
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phene (a tamoxifen site probe) in the presence of mobile phas-
es that contained known levels of m-HPPH or p-HPPH. For 
both digitoxin and cis-clomiphene only small random varia-
tions (±1–4%) in their retention factors were observed as the 
mobile phase concentration of m-HPPH or p-HPPH was var-
ied. The digitoxin site has been found previously to bind phe-
nytoin [7], but the results obtained in this current study indi-
cate that m-HPPH and p-HPPH do not have signifi cant inter-
actions at this site. This may be related to the greater polari-
ty of these metabolites versus phenytoin, which would tend to 
decrease the importance of non-polar interactions in the bind-
ing of these compounds to HSA. Alternatively, this may result 
from steric effects that prevent the binding of these metabo-
lites to the digitoxin site due to the presence of the hydroxyl 
groups on these compounds.
4.3. Competition of phenytoin with m-HPPH and p-HPPH
A third set of experiments investigated the competition 
that occurs on HSA between m-HPPH and p-HPPH and their 
parent compound, phenytoin. This was of interest because of 
the differences noted earlier in this report concerning the asso-
ciation equilibrium constants and number of binding sites for 
phenytoin compared to its metabolites. The results obtained in 
these studies are summarized in Table 3. 
The fi rst series of zonal elution experiments in this sec-
tion were performed by injecting trace amounts of phenytoin 
into mobile phases that contained known concentrations of its 
metabolites. Figure 5 shows the plots obtained when the data 
were analyzed using a 1:1 direct competition model, as rep-
resented by Equation (6). These plots gave linear responses, Figure 4. Results of zonal elution studies using l-tryptophan as a site-specif-
ic probe injected in the presence of mobile phases containing known concen-
trations of: (a) m-HPPH; or (b) p-HPPH when analyzing the data according to 
Equation (5). The best-fi t lines were: (a) y = 0.00091 (±0.00004) x + 0.3933 (
±0.0006); and (b) y = 0.00129 (±0.00003) x + 0.2078 (±0.0006), with correla-
tion coeffi cients of 0.9956 (n = 6) and 0.9986 (n = 7), respectively. The error 
bars represent a range of ±1 S.D. 
Figure 5. Results of zonal elution competition studies using phenytoin inject-
ed into mobile phases containing known concentrations of: (a) m-HPPH; or 
(b) p-HPPH. The best-fi t lines were: (a) y = 0.00144 (±0.00007) x + 0.5325 (
±0.0014); and (b) y = 0.00169 (±0.00008) x + 0.4501 (±0.0017), with correla-
tion coeffi cients of 0.9939 (n = 7) and 0.9939 (n = 7), respectively. The error 
bars represent a range of ±1 S.D. 
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as predicted for direct competition at a single site, with cor-
relation coeffi cients of 0.9939 (n = 7) and 0.9939 (n = 7) for 
the m-HPPH and p-HPPH data, respectively. The best-fi t in-
tercepts were within one standard deviation of the true inter-
cepts, with differences in these values of only 0.14 and 0.55% 
for m-HPPH and p-HPPH. It was possible from the slopes and 
intercepts of these plots to again obtain estimates of the as-
sociation equilibrium constants for m-HPPH and p-HPPH 
with HSA. This gave values of 2.7 (±0.1) × 103 M−1 and 3.8 
(±0.2) × 103 M−1, respectively, which agreed with the num-
bers calculated earlier from Figure 3 and Figure 4. 
Figure 5 indicates that both m-HPPH and p-HPPH had di-
rect competition with phenytoin on HSA. From the experi-
ments described in the last section, it was further determined 
that this competition must be occurring at the indole-benzo-
diazepine site. However, as also stated earlier, phenytoin is 
known to have additional binding regions on HSA and to have 
signifi cant allosteric effects on solutes that bind to other sites 
on this protein [7]. The experiments in Figure 5 did not al-
low such effects to be seen since phenytoin was present in 
only a trace amount compared to its metabolites. To overcome 
this limitation, the reverse experiment was next performed, 
in which the phenytoin metabolites were injected into mobile 
phases that contained known concentrations of phenytoin. The 
results are shown in Figure 6. 
When the data for the competition of p-HPPH with phe-
nytoin were plotted according to the direct competition mod-
el in Equation (6), the results gave a good fi t to a linear re-
gression model, as shown in Figure 6(b), with a correlation co-
effi cient of 0.9913 (n = 5). However, the association equilibri-
um constant estimated from this plot for phenytoin was 1.8 (± 
0.1) × 103 M−1. This value is approximately an order of magni-
tude lower than that found in previous competition studies us-
ing a trace amount of phenytoin and l-tryptophan as a site-se-
lective probe for the indole-benzodiazepine site [7]. As indicat-
ed in Reference [7], this decrease in binding strength for phe-
nytoin can be explained by a negative allosteric effect between 
phenytoin and itself as this drug binds to other regions on HSA. 
This would also be expected to produce a mixed-mode interac-
tion between phenytoin and p-HPPH, where phenytoin can un-
dergo either direct competition with this metabolite or cause a 
negative allosteric effect in the binding of p-HPPH to HSA.
The presence of negative allosteric effects was more clear-
ly indicated in the results for m-HPPH and phenytoin in Fig-
ure 6(a). In this case, when the data were plotted according to 
the direct competition model in Equation (6) distinctly non-
linear behavior was noted. This behavior is consistent with a 
model in which the binding of phenytoin to HSA is having di-
rect competition plus a negative allosteric effect on the bind-
ing of its metabolite to HSA. A similar effect to that seen in 
Figure 5 and Figure 6 has been also reported in earlier studies 
examining the interactions on HSA between phenytoin with l-
tryptophan (i.e., the site-selective probe used in this current 
study for the indole-benzodiazepine site) [7, 20].
Figure 6. Results of zonal elution competition studies using: (a) m-HPPH; 
or (b) p-HPPH injected into the presence of mobile phases containing known 
concentrations of phenytoin. The solid-lines show the best-fi t response when 
the data were analyzed according to a 1:1 direct competition model based on 
Equation (5). The best-fi t lines in these plots were: (a) y = 0.0022 (±0.0003) x
 + 0.9709 (±0.0051); and (b) y = 0.0019 (±0.0001) x + 1.0363 (±0.0024) with 
correlation coeffi cients of 0.9709 (n = 5) and 0.9913 (n = 5), respectively. The 
error bars represent a range of ±1 S.D. 
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5. Conclusions
This report used HPLC-based immobilized HSA columns 
to study binding by the phenytoin metabolites m-HPPH and p-
HPPH to HSA. The results are summarized in Table 4. Self-
competition experiments indicated that these metabolites had 
a single major binding site on HSA. Further work with site-
selective probes indicated that the indole-benzodiazepine site 
(i.e., Sudlow site II) was the location of this binding region. 
Several estimates were obtained for the association equi-
librium constants of these phenytoin metabolites with HSA. 
These values ranged from 2.3 to 4 × 103 M−1 (best estimate, 
3.2 (±1.2) × 103 M−1) for m-HPPH and 5.2–6.2 × 103 M−1 
(best estimate, 5.7 (±0.7) × 103 M−1) for p-HPPH at pH 7.4 
and 37 °C. For each of these estimates, p-HPPH had an asso-
ciation equilibrium constant that was 1.3–2.7 fold higher than 
that for m-HPPH. This indicated the relative importance of the 
hydroxyl group position of these compounds in determining 
their overall binding strength to HSA. 
Both m-HPPH and p-HPPH where found to have direct 
competition with their parent compound, phenytoin, at the in-
dole-benzodiazepine site of HSA. However, experiments us-
ing phenytoin as a competing agent indicated that this drug 
also had negative allosteric interactions on the binding of 
these metabolites to HSA. These results agree with previous 
studies on the binding of phenytoin to HSA and its effects on 
the interactions of HSA with site-selective probes for the in-
dole-benzodiazepine site [7] and [20]. The results of this re-
port also demonstrate the value of using HPLC-based HSA 
columns in the study of drug/metabolite competition. In addi-
tion, these results indicate that signifi cant differences can oc-
cur in both the binding strength and binding regions for drugs 
and their metabolites on HSA.
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